Piret Pharma SRL
1.1 FTEPiret Pharma reported total assets of 675,213 € at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Aug 2026), with 1.1 full-time equivalent.
The score of Piret Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +196 % Total assets -13 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Piret Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Aug 2026
- Year ended 31 Dec 2024filed on 30 Sep 2025
- Year ended 31 Dec 2023filed on 28 Aug 2024
Piret Pharma's financial analysis
- Solvency18.8%sector median: 40.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Piret Pharma
Piret Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0783.830.868
- VAT number
- BE0783830868
- Peppol
- Registered · 0208:0783830868 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 25 Mar 2022
- Registered office
- 6030 Charleroi
- Size
- Micro · 1.1 FTE
- Latest accounts
- 2025 · filed on 27 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Piret Pharma (SRL) has been based in Charleroi since 2022, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 35,490 € and equity of 126,674 €; its revenue is not published. With 1.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 18.8%, below the median of its sector (40.1%).
Companies similar to Piret Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie DE Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- Apotheek Vanswijgenhoven Retail sale of pharmaceutical products Sint-Truiden · balance sheet 684,354 €
- Mansion-Tassin Retail sale of pharmaceutical products Beyne-Heusay · balance sheet 648,936 €
- MieTon Retail sale of pharmaceutical products Hoogstraten · balance sheet 705,749 €
- Corum Retail sale of pharmaceutical products Ghent · balance sheet 641,387 €
- Maudens Jeroen Retail sale of pharmaceutical products Sint-Genesius-Rode · balance sheet 633,969 €
- Caro Pharma Retail sale of pharmaceutical products Erquelinnes · balance sheet 593,057 €
- Emanuel - VAN Hauwermeiren Retail sale of pharmaceutical products Dendermonde · balance sheet 588,306 €
Frequently asked questions about Piret Pharma
What is the revenue of Piret Pharma?
Piret Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Piret Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0783830868 for Piret Pharma, if the company is VAT-registered. Its company number (CBE) is 0783.830.868.
Where is the registered office of Piret Pharma?
According to the CBE register, the registered office of Piret Pharma is in 6030 Charleroi.
What is the equity of Piret Pharma?
At the close of the 2025 financial year, the equity of Piret Pharma amounts to 126,674 €, a solvency of 18.8% of total assets.
How many people work at Piret Pharma?
1.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Piret Pharma?
The register lists 3 active mandates at Piret Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Piret Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →